Chlorpromazine's Potential Role in Palliating Distressing Symptoms Associated With Hyperactive Delirium in Patients at End of Life.
J Palliat Med
; 26(6): 826-830, 2023 06.
Article
em En
| MEDLINE
| ID: mdl-36847737
ABSTRACT
Background:
The hyperactive subtype of delirium is characterized by agitation, restlessness, delusions, and/or hallucinations, which commonly present near end of life (EoL). Symptom relief often requires the use of medications, such as chlorpromazine (CPZ), to reduce patient distress by inducing proportional sedation.Objective:
The purpose of this study was to evaluate CPZ's potential role in managing the distress of hyperactive delirium in patients receiving EoL care.Methods:
A retrospective observational study among hospitalized patients with advanced cancer at EoL between January 2020 to December 2021.Results:
Sustained improvement in symptoms of delirium was seen in 80% of patients as identified in the palliative psychiatrist's progress notes. Meanwhile, 75% of patient's improvement was reported in nursing-driven Delirium Observation Screening Scale.Conclusion:
This study elucidates that at doses of â¼100 mg/day, CPZ is potentially an effective medication for patients with advanced cancer, experiencing hyperactive delirium in their final week of life.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Delírio
/
Neoplasias
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article